Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent targeting Bruton tyrosine kinase in the B-cell receptor signaling pathway, is highly effective in several malignancies. Its ac...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Rogers, Kerry A., Andritsos, Leslie A., Wei, Lai, McLaughlin, Eric M., Ruppert, Amy S., Anghelina, Mirela, Blachly, James S., Call, Timothy, Chihara, Dai, Dauki, Anees, Guo, Ling, Ivy, S. Percy, James, Lacey R., Jones, Daniel, Kreitman, Robert J., Lozanski, Gerard, Lucas, David M., Ngankeu, Apollinaire, Phelps, Mitch, Ravandi, Farhad, Schiffer, Charles A., Carson, William E., Jones, Jeffrey A., Grever, Michael R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2021
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8225920/
https://ncbi.nlm.nih.gov/pubmed/33754642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009688
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia